SCNI
Income statement / Annual
Last year (2025), Scinai Immunotherapeutics Ltd's total revenue was $1.31 M,
an increase of 99.24% from the previous year.
In 2025, Scinai Immunotherapeutics Ltd's net income was -$8.31 M.
See Scinai Immunotherapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.31 M |
$658.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$3.96 M
|
$1.24 M
|
$0.00
|
$0.00
|
$747.65 K
|
$708.92 K
|
$461.69 K
|
$72.32 K
|
$123.55 K
|
$0.00
|
| Gross Profit |
-$2.65 M
|
-$580.00 K
|
$0.00
|
$0.00
|
-$747.65 K
|
-$708.92 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
-2.02
|
-0.88
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.37 M
|
$5.53 M
|
$5.21 M
|
$5.77 M
|
$2.62 M
|
$14.42 M
|
$19.88 M
|
$19.27 M
|
$5.58 M
|
$2.44 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.52 M
|
$2.53 M
|
$4.51 M
|
$5.30 M
|
$7.42 M
|
$4.69 M
|
$2.81 M
|
$1.38 M
|
$1.40 M
|
$1.07 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$9.00 K
|
$0.00
|
$1.00
|
$1.00
|
$0.00
|
-$38.24 K
|
-$186.00 K
|
-$416.00 K
|
| Operating Expenses |
$4.89 M
|
$8.06 M
|
$9.71 M
|
$11.06 M
|
$10.05 M
|
$19.11 M
|
$22.69 M
|
$20.61 M
|
$6.80 M
|
$3.09 M
|
| Cost And Expenses |
$8.85 M
|
$9.30 M
|
$9.71 M
|
$11.06 M
|
$10.79 M
|
$19.82 M
|
$22.69 M
|
$20.61 M
|
$6.80 M
|
$3.09 M
|
| Interest Income |
$20.00 K
|
$100.47 K
|
$3.92 M
|
$3.05 M
|
$928.76
|
$581.56
|
$8.30 K
|
$1.35 M
|
$5.04 K
|
$14.38 K
|
| Interest Expense |
$359.00 K
|
$1.44 M
|
$3.80 M
|
$0.00
|
$3.36 M
|
$338.76 K
|
$4.28 M
|
$3.78 M
|
$20.45 K
|
$100.00
|
| Depreciation & Amortization |
$1.42 M
|
$1.65 M
|
$514.00 K
|
$562.00 K
|
$747.65 K
|
$708.92 K
|
$461.69 K
|
$72.32 K
|
$123.55 K
|
$162.32 K
|
| EBITDA |
-$6.53 M |
-$6.99 M |
-$2.19 M |
-$5.23 M |
-$10.05 M |
-$19.11 M |
-$22.21 M |
-$20.54 M |
-$6.67 M |
-$2.93 M |
| EBITDA Ratio |
-4.98
|
-10.62
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-5.75
|
-13.13
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$765.00 K
|
$13.43 M
|
$3.21 M
|
$5.27 M
|
-$1.58 M
|
$18.52 M
|
-$8.93 M
|
-$2.85 M
|
-$3.13 M
|
$704.94 K
|
| Income Before Tax |
-$8.31 M
|
$4.80 M
|
-$6.50 M
|
-$5.80 M
|
-$12.38 M
|
-$1.30 M
|
-$31.62 M
|
-$23.46 M
|
-$9.93 M
|
-$2.38 M
|
| Income Before Tax Ratio |
-6.34
|
7.29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$8.31 M
|
$4.80 M
|
-$6.50 M
|
-$5.80 M
|
-$12.38 M
|
-$1.30 M
|
-$31.62 M
|
-$23.46 M
|
-$9.93 M
|
-$2.38 M
|
| Net Income Ratio |
-6.34
|
7.29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-36 |
60 |
-64000 |
-160000 |
-3507480 |
-467560 |
-15488000 |
-14358000 |
-7902800 |
-2823200 |
| EPS Diluted |
-36 |
60 |
-64000 |
-160000 |
-3507480 |
-467560 |
-15488000 |
-14358000 |
-7902800 |
-2823200 |
| Weighted Average Shares Out |
$233.49 K
|
$80.64 K
|
$97.00
|
$47.00
|
$3.00
|
$2.00
|
$8.17 K
|
$6.54 K
|
$5.03 K
|
$3.38 K
|
| Weighted Average Shares Out Diluted |
$233.49 K
|
$80.64 K
|
$97.00
|
$47.00
|
$3.00
|
$2.00
|
$8.17 K
|
$6.54 K
|
$5.03 K
|
$3.38 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
